COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
|
|
|
- Emil Gaines
- 5 years ago
- Views:
Transcription
1 UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva
2 MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have assumed procurement of 162 mid6range vial sizes for each drug and that a vial cannot be reused once opened.thismethodologywaschosentorepresentthemostlikelypracticalscenario.while vial sizes may be available in a number of different sizes for each drug, these sizes do not alwayscorrespondtotheexactdosageapatientwouldreceive.forexample,ifapatientwitha body surface area of 2m2 requires a dose of a drug equal to 4mg/m2, 8mg total would be requiredforthatdose.however,iftheonlyavailablevialsizeis10mg,thepricefortreating thatpatientwouldbethecostofprocuringthe10mgvial,notjustthecostofthe8mgactually used.ifmultiplepatientswiththesamechemotherapyregimenareseenonthesameday,it would be possible for the staff to use the additional dosage for another patient and avoid waste.however,giventhesmallerpatientvolumesinlowresourcecountries,thisscenariois lesslikely.overageamountscouldalsobeminimizedbyprocuringsmallervialsizes.however, procurementofsmallvialsizescanbedifficultandunlikelyinpracticeformanycountries.the chosen methodology leads to conservative estimates, as prices can be reduced by either procuringsmalleradditionalvialsizesand/ortreatingmorepatientswiththesamediseaseon thesamedays. All drug prices are calculated using Management Sciences for Health 2013 International Drug PriceIndicator.Pricesreflectthelowestaveragecostavailable. Moredetailscanbeprovidedonmethodology,onrequest. References:) MSH(ManagementSciencesforHealth).2014.InternationalDrugPriceIndicatorGuide,2013 Edition.(Updatedannually.)Medford,Mass.:MSH. Scenarios 1. DiffuseLargeB6cellLymphoma 2. EarlyStageBreastCancer 3. Hodgkin slymphoma 4. Kaposi ssarcoma 5. Rhabdomyosarcoma 6. StageIIIColonCancer 7. WilmsTumor
3 EARLYSTAGEBREASTCANCER Scenario:anERpositive/HER2positivewomanwithabodysurfaceareaof1.7m 2 andabodyweightof 62kg. EssentialRegimen:ACGT Doxorubicin/Cyclophosphamidefollowedbypaclitaxel(4cyclesofeach) UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Doxorubicin $6.48per50mgvial 12vials $77.75 $8.75per500mgvial 4500mgvials+ $46.79 Cyclophosphamide $2.89per1gvial 41gvials Paclitaxel $7.42per100mgvial 12vials $88.27 Tamoxifen $0.03per20mgtab6cap 1,825(1dailyfor5years) $60.23 TotalCost $ AdvancedRegimenIncludingTrastuzumab,forHER2Positivedisease:ACGTH Doxorubicin/Cyclophosphamidefollowedbypaclitaxel/trastuzumab UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Doxorubicin $6.48per50mgvial 12vials $77.75 $8.75per500mgvial 4500mgvials+ $46.79 Cyclophosphamide $2.89per1gvial 41gvials Paclitaxel $7.42per100mgvial 24vials $ Tamoxifen $0.03per20mgtab6cap 1,825(1dailyfor5years) $60.23 Trastuzumab $6.27permg 6,448mg $40, TotalCost $40, **Methodology)addendum:Ifacountryprocuresonly50mgvialsofDoxorubicin,3vialswillberequired foreachcyclewithintheac6tregimen,resultinginatotalof$77.74forafullcourseofdoxorubicin. Thiscalculationamountstoadrugwasteof192mgoverthecourseoftreatment.Ifonly10mgvialscan beprocured,thecostoftreatmentwouldincreaseto$104.56butlesswastewouldbeincurred.ifboth sizevialscouldbeprocured,verylittlewastewouldbeexpectedandthefullcostfortreatmentwould beonly$62.29.
4 DIFFUSELARGEBGCELLLYMPHOMA CHOPScenario Apatientwithabodysurfaceareaof1.8m 2 receivingr6chopfor6cycles. EssentialRegimen:CHOP:Chemotherapyonly,6cycles UnitSizeandCost Unitsrequiredfor entireregimen TotalCost Cyclophosphamide $8.75per500mgvial $2.89per1gvial 6x500mgvials+ 6x1gvials $69.83 Doxorubicin $6.48per50mgvial 12vials $77.75 Vincristine $2.61per1gvial 18vials $47.02 Prednisone $0.03per100mgtab6cap 30tab6caps $0.81 TotalCost $ RGCHOPScenario Apatientwithabodysurfaceareaof1.8m 2 receivingr6chopfor6cycles. AdvancedRegimen:RGCHOP:Chemotherapyplusmonoclonalantibody,6cycles UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment $14.65per10mg/ml 408ampoules Rituximab ampoule $5, Cyclophosphamide $8.75per500mgvial $2.89per1gvial 6500mgvials+ 61gvials $69.83 Doxorubicin $6.48per50mgvial 12vials $77.75 Vincristine $2.61per1gvial 18vials $47.02 Prednisone $0.03per100mgtab6cap 30tab6caps $0.81 TotalCost $6,171.79
5 STAGEIIICOLONCANCER RoswellParkScenario:apatientwithabodysurfaceareaof1.8m 2 receivingleucovorinondays1,8,15 withina28daycycleand56fuondays1,8,15withina28dcycleforatotalof6cycles EssentialRegimen:6cyclesofLeucovorin+5GFU UnitSizeandCost #ofunitsnecessaryfora fullcourseoftreatment TotalCost Leucovorin(calcium $2.35per50mgvial 324vials folinate) $ FU(Fluorouracil) $0.11per50mgampoule 324vials $34.34 TotalCost $ mfolfox6scenario:apatientwithabodysurfaceareaof1.8m 2 receivingleucovorin,56fuand Oxaliplatinover6cycles AdvancedRegimen:6cyclesof14dayseach=Leucovorin@400mg/m2onday1+5GFU@400mg/m2 onday1+5gfu@1200mg/m2dailyondays1+2+oxaliplatin@85mg/m2onday1 UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Leucovorin(calcium $2.35per50mgvial folinate) 86vials $ FU(Fluorouracil) $0.11per50mgampoule 86vials $ FU(Fluorouracil) $0.11per50mgampoule 518vials $54.95 Oxaliplatin $7.93per50mgvial 24vials $ TotalCost $457.13
6 HODGKIN SLYMPHOMA LimitedDiseaseScenario:apatientwithabodysurfaceareaof1.8m 2 andlimiteddiseasereceiving3 cyclesofabvd:2doseseach28days,foratotalof14fulldoses. EssentialRegimen:ABVD:2G4cyclesforlimiteddisease(repeatedevery28days) UnitSizeandCost #ofunitsnecessaryfora fullcourseoftreatment TotalCost Doxorubicin $6.48per50mgvial 6vials $38.87 Bleomycin $11.13per15mgvial 12vials $ Vinblastine $8.84per10mgvial 12vials $ Dacarbazine $7.16per200mgvial 24vials $ TotalCost $ AdvancedDiseaseScenario:apatientwithabodysurfaceareaof1.8m 2 andadvanceddisease receiving7cyclesofabvd:2doseseach28days,foratotalof14fulldoses. EssentialRegimen:ABVD:6G8cyclesforadvanceddisease(repeatedevery28days) UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Doxorubicin $6.48per50mgvial 14vials $90.71 Bleomycin $11.13per15mgvial 28vials $ Vinblastine $8.84per10mgvial 28vials $ Dacarbazine $7.16per200mgvial 56vials $ TotalCost $1, **Methodology)addendum:Whilewastewillbeincurredforeachdruglistedabove,thecalculations representtheleastwastepossible.doxorubicinispricedattheclosestvialsizeavailableandbleomycin, Vinblastine,andDacarbazineareallpricedattheonlyvialsizepricingavailable.
7 KAPOSI SSARCOMA Scenario:apatientwithabodysurfaceareaof1.8m 2 andarelapsedcaseofkaposi ssarcoma EssentialRegimen: Either:Paclitaxel,100mg/m2every2weeksovera6monthperiod UnitSizeandCost #ofunitsnecessaryfora fullcourseoftreatment TotalCost Paclitaxel $7.42per100mgvial 24vials $ Or:PLD,20mg/m2every2weeksovera6monthperiod UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment PLD(Doxilgeneric) $468per50mgvial 8vials $3, HIVGPositiveScenario:anHIV6positivepatientwithaBSAof1.8m 2 receivingabvfor6cycles AdvancedRegimen:ABVforHIVGpositivePatients:6cycles UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Vinblastine $8.84per10mgvial 12vials $ Bleomycin $11.13per15iuvial 12vials $ Doxorubicin $6.48per50mgvial 6vials $38.87 $ HIVGNegativeScenario:anHIV6negativepatientwithaBSAof1.8m 2 receivingabvfor6cycles AdvancedRegimen:ABVforHIVGnegativePatients:6cycles UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Vinblastine $8.84per10mgvial 12vials $ Bleomycin $11.13per15iuvial 12vials $ Doxorubicin $6.48per50mgvial 12vials $77.75 $317.30
8 COST CONSIDERATIONS Step2Regimen:Vincristine:1.4mg/m 2 fortnightlyfor6cycles UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Vincristine $2.61per1mgvial 18vials $47.02 Step2Regimen:Vincristine/Bleomycin:6cyclesfor6cycles UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Vincristine $2.61per1mgvial 18vials $47.02 Bleomycin $11.13per15iuvial 12vials $ $ **Methodology)addendum:Whilewastewillbeincurredforeachdruglistedabove,thecalculations representtheleastwastepossible.doxorubicinandpaclitaxelarepricedattheclosestvialsizeavailable andvinblastineandbleomycinarebothpricedattheonlyvialsizepricingavailable.
9 RHABDOMYOSARCOMA EssentialScenario:ayoungpatientwithabodysurfaceareaof0.6m 2 receivingvacover12cycles EssentialRegimen:12cyclesofVAC UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Cyclophosphamide $8.75per500mgvial 24vials $ Vincristine $2.61per1mgvial 12vials $31.34 ActinomycinGD $18.16per500mcgvial 24vials $ TotalCost $ AdvancedScenario:ayoungpatientwithabodysurfaceareaof0.6m2receivingtheIrinotecan6 Vincristineregimenover12cycles AdvancedRegimen:12cyclesofIrinotecanGVincristine:50mg/m2ofIrinotecanfor5dayseachcycle and1.5mg/m2(max2mg)ofvincristineforonedayeachcycle UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Irinotecan $51.59per20mgvial 120vials $6, Vincristine $2.61per1mgvial 12vials $31.34 TotalCost $6,222.14
10 WILM STUMOR EssentialScenario:ayoungpatientwithlocalizeddiseaseatdiagnosis:Stage1Intermediaterisk(IR) andabodysurfaceareaof0.6m 2 andweightequalto15kg. EssentialRegimen:PreGOp:4dosesover4weeksofvincristine(1.5mg/m2,maximum2mg)and2 dosesinweeks1&3ofactinomycind(45ug/kgiv,maximum2mg);postgop(4gweeksofvincristine (1.5mg/m2,maximum2mg)and1doseinweek1ofactinomycinD(45ug/kgIV,maximum2mg) UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Vincristine $2.61per1mgvial 8vials $20.90 ActinomycinGD $18.16per500mcgvial 6vials $ TotalCost $ AdvancedScenario:ayoungpatientwithMetastaticWilm stumorandabodysurfaceareaof0.6m2 andweightequalto15kg. AdvancedRegimen:PreGOp:9dosesover9weeksofvincristine(1.5mg/m2,maximum2mg)and5 doses(everyotherweeks)ofactinomycind(45ug/kgiv,maximum2mg)and3dosesdoxorubicin 50mg/m2;postGop(11Gweeksofvincristine(1.5mg/m2,maximum2mg)and5dosesofactinomycinD (45ug/kgIV,maximum2mg)and5dosesDoxorubicin50mg/m2 UnitSizeandCost #ofunitsnecessaryfora TotalCost fullcourseoftreatment Vincristine $2.61per1mgvial 20vials $52.24 ActinomycinGD $18.16per500mcgvial 20vials $ Doxorubicin $6.48per50mgvial 8vials $51.83 TotalCost $467.35
11 Medicine, *not$on$the$who$eml$18th$ed Afatinib* Aflibercept* Strength Dosage,form Unit,price, Lowest (US$), Median, (US$) Highest, (US$) MSH,,International,Drug,Price,Indicator,Guide,2013,Edition, Buyer,prices,US$ No.,of,prices, High/low, ratio, Median, (US$), Supplier,prices,US$, If,one,pricing,source Allopurinol0 1000mg0 tab3cap per0tab mg0 tab3cap per0tab (JMS): Anastrozole* 10mg0 tab3cap per0tab letrozole* 2.50mg tab3cap per0tab Exemestane* Asparaginase 10,0000iu/ml0 vial only0one0pricing0source00(namibia): /ml 1,0000iu/ml ampoule only0one0pricing0source0(costa0rica):03.7/ml0 Bendamustine* Bevacizumab* Bicalutamide* 500mg0 tab3cap per0tab Bleomycin 150iu vial per0vial (MEDS):015.9 Calcium0folinate/leucovorin 150mg tab3cap per0tab mg vial per0vial Capecitabine* 1500mg tab3cap only0one0pricing0source0(saf): /tab3cap0 5000mg tab3cap per0tab Carboplatin0 1500mg vial per0vial (platinum0class0 4500mg vial per0vial Cetuximab* Cisplatin* 100mg vial only0one0pricing0source0(saf): /ml0 10mg/ml vial only0one0pricing0source0(barbados): /ml0 0500mg vial per0vial Chlorambucil 20mg tab3cap per0tab Crizotinib* Cyclophosphamide 1g vial per0vial (MSD/TANZ): mg0 vial only0one0pricing0source0(namibia): /vial0 (MSD/TANZ): mg0 vial per0vial mg tab3cap per0tab Cytarabine 1000mg0 vial per0vial mg0 vial per0vial Dacarbazine 2000mg vial per0vial Dactinomycin 5000mcg vial per0vial Daunorubicin 200mg0 vial per0vial Dexamethasone 0.50mg0 tab3cap per0tab mg/ml0 ampoule per0ml mg/ml0 ampoule only0one0pricing0source0(drc):00.090/ml0 Docetaxel 200mg0 vial per0vial mg0 vial0 per0vial Doxorubicin 100mg0 vial per0vial mg0 vial per0vial Doxorubicin0liposomal* Erlotinib* Etoposide 200mg/ml vial per0ml Filgrastim*0 3000mcg/ml ampoule per0ml Fludarabine*0phosphate 500mg vial per0vial Fluorouracil0 500mg/ml ampoule per0ml Gefitinib* Gemcitabine* 1g vial per0vial mg vial per0vial Hydroxycarbamide/hydroxyure 5000mg tab3cap per0tab
12 Medicine, *not$on$the$who$eml$18th$ed Strength Dosage,form Unit,price, Lowest (US$), Median, (US$) Highest, (US$) MSH,,International,Drug,Price,Indicator,Guide,2013,Edition, Buyer,prices,US$ No.,of,prices, High/low, ratio, Median, (US$), Supplier,prices,US$, If,one,pricing,source Idarubicin* 100mg vial per0vial only0one0pricing0source0(saf): /vial0 Ifosfamide 10g vial per0vial g0 vial only0one0pricing0source0(saf): /vial0 5000mg0 vial per0vial Imatinib* 1000mg0 tab3cap per0tab mg0 tab3cap per0tab Irinotecan* Leuprolide0acetate* Melphalan* 20mg tab3cap per0tab Mercaptopurine 500mg0 tab3cap per0tab Mesna 1000mg/ml ampoule per0ml mg0 ampoule per0amp Methotrexate 250mg/ml vial0 per0ml AMSTELFAR: mg0 tab3cap per0tab DURBIN: Mifamurdine* Oxaliplatin 1000mg0 vial per0vial (platinum) 500mg0 vial per0vial Paclitaxel 1000mg0 vial per0vial mg/ml vial per0ml Panitumumab* Prednisone 200mg0 tab3cap per0tab (UNFPA): (under0class0representative0 500mg0 tab3cap only0one0pricing0source0(peru): /tab3cap0 prednisolone) 50mg0 tab3cap per0tab Premetexed* Procarbazine Regorafenib* Rituximab* 100mg/ml ampoule0 per0ml Sunitinib* Tamoxifen 100mg0 tab3cap only0one0pricing0source0(saf): /tab3cap0 (IDA): mg0 tab3cap per0tab Thioguanine 400mg tab3cap only0one0pricing0source0(namibia): /tab3cap Thiotepa* Trastuzumab* Tretinoin* Vinblastine 100mg0 vial per0vial Vincristine 10mg0 vial per0vial Vinorelbine*
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
An introduction to the Essential Medicines concept: balancing innovation with public health priorities
An introduction to the Essential Medicines concept: balancing innovation with public health priorities WHO HQ, Geneva 11 October 2017 Nicola Magrini Secretary, WHO Expert Committee on the Selection and
Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
MEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
MASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
Adult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
DRUG PROPERTIES YOU NEED TO KNOW
Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
Guidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
REGULATORY INFORMATION
REGULATORY*INFORMATION/*CANCER*MEDICINES* Summary'of'regulatory'status'of'the'medicines' As#recommended#in#the#EML#Secretariat s#instructions#regarding#applications#for#the#addition#of#new# medicines#
SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
DRUG PROPERTIES YOU NEED TO KNOW
jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 8 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class b. resistance 2. Pharmacokinetics 3. Therapeutic uses 4. Major side effects/toxicities
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
CANCER PREVENTION AND ACCESS TO MEDICINES. Gracemarie Bricalli ESMO Head of International Affairs
CANCER PREVENTION AND ACCESS TO MEDICINES Gracemarie Bricalli ESMO Head of International Affairs ESMO s 2020 Vision: Access to cancer care ESMO s 2020 vision statement recognises that progress in the management
Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
DRUGS YOU NEED TO KNOW
jfitzake@d.umn.edu Page 1 of 7 DRUGS YOU NEED TO KNOW ALKYLATING AGENTS (blue cards) BUSULFAN CARMUSTINE (BCNU) CYCLOPHOSPHAMIDE DACARBAZINE LOMUSTINE (CCNU) MECHLORETHAMINE MELPHALAN THIOTEPA NATURAL
1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.
WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black
Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
Emetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
World Health Organization: Essential Medicines and Devices for Cancer:
World Health Organization: Essential Medicines and Devices for Cancer: Principles, Methodologies, and Outcomes Lawrence N. Shulman, MD Abramson Cancer Center, University of Pennsylvania Partners In Health
1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000
ردیف کد ژنریک نام ژنریک مبلغ پوشش وزارت بهداشت مبلغ پوشش بیمه مبلغ پرداخت بیمار درصد پرداخت بیمار قیمت اعالمی وزارت بهداشت نام تجاری 1 17 ACITRETIN 10MG CAP 20,000 10.0 2,000 14,000 4,000 2 18 ACITRETIN
Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
Haematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
Guideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
Acute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy
DRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
Job title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
For Health Professionals Who Care For Cancer Patients EDITOR S CHOICE
Inside This Issue: For Health Professionals Who Care For Cancer s March 2019 Vol. 22 No. 3 Editor s Choice New Programs: Rituximab Protocols in CLL/SLL Updated (LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFLUDR,
Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma
Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for high grade and Burkitt s lymphoma used in the
The AngCN Antiemetic Guidelines
The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction
Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
FOR A HIGHER DEGREE OF CONFIDENCE
SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS. > Introduction Manufacturing specialized products in a pharmaceutical manufacturing environment has a specific set of requirements
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
CHEMOTHERAPY/ ANTICANCER DRUGS/ NEOPLASTIC AGENTS
CHEMOTHERAPY/ 1 Oncology, Misc, Vaccines ANTICANCER DRUGS/ NEOPLASTIC AGENTS Important Terms: Cancer: A group of diseases involving abnormal cell growth with the potential to invade or spread to other
AD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25
A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475,
ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY
ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed
General Authorization Criteria for ALL Agents and Indications:
Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed
Working Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
Disease Site Sub-Disease Site Intent Regimen Code Regimen Details Status (as of October 17, 2017) Breast Not Applicable Adjuvant / Curative
ST-QBP Regimen Request Status for 2017/18 Below are status of regimen requests submitted for funding considerations in FY 17/18 Q1 & Q2. Requests with status will be updated on the ST-QBP website and will
SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS
SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS Manufacturing specialized products in a pharmaceutical
Subject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
Pharmacy Prior Authorization Colony Stimulating Factor (CSF)/Myeloid Growth Factor (MGF) Clinical Guideline
Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed
THE ESMO INTERNATIONAL ANTINEOPLASTIC MEDICINES SURVEY: HOW AVAILABLE ARE THE WHO ESSENTIAL CANCER MEDICINES?
THE ESMO INTERNATIONAL ANTINEOPLASTIC MEDICINES SURVEY: HOW AVAILABLE ARE THE WHO ESSENTIAL CANCER MEDICINES? Alexandru ENIU, MD, PhD Chair, ESMO Global Policy Committee Department of Breast Tumors Cancer
Patient 1: Patient 2:
Appendix A Compiled by Dr. Raymond Ngeh and Dr. Robert Luk Clinical notes and PET/CT scan images of eleven patients: 1. Middle age woman has cancer of the pancreas in the body of the gland. After just
Committee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
Year III Pharm D. Dr. V. Chitra
Year III Pharm D. Dr. V. Chitra 50.2 Rang Etiolopathology Cell Cycle = Growth, Division 18_01_cell_cycle.jpg Characteristics of Cancer Cells The problem: Cancer cells divide rapidly (cell cycle is accelerated)
Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
Pharmacy Prior Authorization Colony Stimulating Factors Clinical Guideline. Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF)
Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed
Managements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
Part B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
Introduction to Antineoplastic Prescribing
Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand
BC Cancer Benefit Drug List March 2018
Page 1 of 56 DEFNTONS Class eimbursed for active cancer or approved treatment or approved indication only. eimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program
HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1
drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A
Northern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
Guidelines for the Management of Extravasation (Version 5 May 2012)
Guidelines for the Management of Extravasation (Version 5 May 2012) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT NECDAG
Cancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
CCC Chemotherapy Protocols V9.0
CCC Chemotherapy Protocols V9.0 General observations 3 Breast cancer 5 Gastrointestinal cancer Oesophagus 17 Gastric 19 Pancreas 22 Cholangiocarcinoma 24 Hepatocellular carcinoma 25 Neuroendocrine tumours
BC Cancer Benefit Drug List April 2018
Page 1 of 55 DEFNTONS Class estricted Funding () eimbursed for active cancer or approved treatment or approved indication only. eimbursed for approved indications only. Completion of the BC Cancer Compassionate
An assessment of the price of oncology drugs in Ukraine 2015
An assessment of the price of oncology drugs in Ukraine 2015 Prashant Yadav University of Michigan October 2016 The views and opinions expressed in this report are those of the author and should not be
Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
Product Visual Guide
Product Visual Guide Teamwork A team with an unflinching faith in one another is one of our core strength. Excellence Achieving excellence is not the end result, we begin with excelling in any endeavor.
Antiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy
Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy For approvals and version control see Document Management Record
Guidelines for the Management of Extravasation
Guidelines for the Management of Extravasation (Version 5.5-04 Nov 2016) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT
Subject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
Contents Trials. Dose guidelines. Calvert formula Issue Date: January Author: No: Copy. Pagee 1 of 21. Issue.
Chapter 1: General information Contents Chapter 1: General information... 1 General observations... 2 Protocol Additions 2013... 2 Cancer Drugs Fund... 2 Off Protocol Treatment Policy... 2 Trials... 2
Lisa M. Hess Diane Michael Daniel S. Mytelka Julie Beyrer Astra M. Liepa Steven Nicol
Gastric Cancer (2016) 19:607 615 DOI 10.1007/s10120-015-0486-z ORIGINAL ARTICLE Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective
Part B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS
ICON Formulary - November 2016 Class Medicine Name Nappi Strength Form Size Route Manufacturer Abiraterone Acetate ZYTIGA 250 720690001 250 mg 120 ORAL JANSSEN PHARMACEUTICALS Aldesleukin CHIRON IL-2 18
18th Expert Committee on the Selection and Use of Essential Medicines. Reviewer No. 1 checklist for:
18th Expert Committee on the Selection and Use of Essential Medicines Reviewer No. 1 checklist for: Review of medicines for the treatment of common tumours in Children In the WHO Essential Medicines List
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
Trust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
Early Dialogue in HTA Yes, but how to bridge the gap?
Early Dialogue in HTA Yes, but how to bridge the gap? EUNetHTA, September 14, 2017 Dr. h.c. Cees Smit, Patient expert, EGAN/VSOP Dept. Clin. Epidemiology, LUMC, Leiden My experience Hemophiliac, 66 years
To help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot
Antiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
Ovarian Cancer. compendia TREATMENT OF
drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management
VMG Pharmaceuticals Pvt. Ltd.
S. No. Product Name S trength Dos age form Oncology 1 A nastrazole 1 mg Tablets 2 Bicalutamide 50 mg Tablets 3 Bleomycin 15units,30units Injection 4 Bortezomib 3.5 mg Injection 5 Capecitabine 500 mg Tablets
Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication
ST-QBP: Systemic Treatment Quality-Based Program (formerly STFM) DF: Drug Formulary GYNECOLOGICAL SKIN HEMATOLOGY ST- QBP
Updates from October 17, 2017 Please note that the following are regimen updates applicable to webpage documents and/or Drug Formulary s regimen monographs, as indicated by checkmarks. : Systemic Treatment
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG